SLN Share Price Performance
US$11.72
6.34 (117.84%)
62.4% undervalued intrinsic discount
US$31.20
Fair Value
Price US$11.72
AnalystConsensusTarget US$31.20
AnalystHighTarget US$74.31
Fair ValueUS$31.20
Share Pricen/a
Seeking Alpha • Jul 12
Silence Therapeutics plc Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
SLN Community Narratives
AN
Fair Value
·Fair Value US$31.2 62.4% undervalued intrinsic discount
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value
·Fair Value US$74.31 84.2% undervalued intrinsic discount
Advancements In RNAi Will Harness Aging Healthcare Demand
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
Silence Therapeutics is betting on gene-silencing medicines, and early study results plus a major drug-company tie-up suggest its lead programs could move into larger trials and new markets. The big question is whether it can land the partners and funding it needs before losses and rising research costs squeeze the business.Read more
AN
US$31.2
62.4% undervalued intrinsic discount
Fair Value
Profit Margin
18.98%
Future PE
330.71x
Price in 2029
US$38.62
Advancements In RNAi Will Harness Aging Healthcare Demand
Key Takeaways Strong clinical progress and unique program design could accelerate commercialization, market share gains, and pricing power, positioning Silence for significant margin and revenue growth. Expanding pipeline, regained global rights, and preclinical advances in RNAi therapeutics create long-term advantage and substantial high-margin revenue opportunities beyond current market expectations.Read more
AN
US$74.31
84.2% undervalued intrinsic discount
Fair Value
Profit Margin
14.17%
Future PE
308.57x
Price in 2028
US$89.05
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
SLN: Upcoming Phase 2 Data And ATM Program Will Shape Upside Potential
Fair Value: US$31.2 62.4% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Advancements In RNAi Will Harness Aging Healthcare Demand
Fair Value: US$74.31 84.2% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Silence Therapeutics plc Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -1.59
- 79.50%
- -8,943.86%
- 0%
About SLN
- Founded
- 1994
- Employees
- 88
- CEO
- WebsiteView website
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
